Table 5 The initial recurrence patterns of gastric cancer patients receiving curative surgery with or without FLI1 hypermethylation in plasma samples according to MSI/EBV status
|  | MSI+ or EBV+ (n = 28) | MSI− and EBV− (n = 65) | ||||
|---|---|---|---|---|---|---|
FLI1 hypermethylation | FLI1 hypermethylation | |||||
Without n = 10 | With n = 18 | P value | Without n = 41 | With n = 24 | P value | |
Total recurrence | 6 (60.0) | 9 (50.0) | 0.611 | 15 (36.6) | 14 (58.3) | 0.089 |
Locoregional recurrence | 0 | 3 (16.7) | 0.172 | 7 (17.1) | 7 (29.2) | 0.252 |
Hepatoduodenal ligament | 0 | 1 (5.6) | 0.448 | 2 (4.9) | 3 (12.5) | 0.266 |
Abdominal wall | 0 | 2 (11.1) | 0.274 | 4 (9.8) | 5 (20.8) | 0.212 |
Perigastric area | 0 | 0 | – | 1 (2.4) | 0 | 0.441 |
Anastomosis | 1 (10.0) | 4 (22.2) | 0.418 | 3 (7.3) | 2 (8.3) | 0.882 |
Distant metastasis | 5 (50.0) | 6 (33.3) | 0.387 | 11 (26.8) | 10 (41.7) | 0.217 |
Peritoneal dissemination | 1 (10.0) | 2 (11.1) | 0.927 | 7 (17.1) | 3 (12.5) | 0.622 |
Hematogenous metastasis | 4 (40.0) | 3 (16.7) | 0.172 | 2 (4.9) | 5 (20.8) | 0.045 |
Liver | 2 (20.0) | 3 (16.7) | 0.825 | 0 | 4 (16.7) | 0.007 |
Lung | 2 (20.0) | 0 | 0.119 | 2 (4.9) | 0 | 0.272 |
Bone | 1 (10.0) | 0 | 0.172 | 2 (4.9) | 1 (4.2) | 0.895 |
Distant lymphatic recurrence | 0 | 2 (11.1) | 0.274 | 3 (7.3) | 5 (20.8) | 0.109 |
Virchow’s node | 0 | 0 | – | 0 | 1 (4.2) | 0.188 |
Lymphangitis carcinomatosa | 0 | 0 | – | 2 (4.9) | 0 | 0.272 |
Para-aortic lymph node | 0 | 2 (11.1) | 0.274 | 1 (2.4) | 5 (20.8) | 0.013 |